ATE465168T1 - Xylo-lna analoge - Google Patents

Xylo-lna analoge

Info

Publication number
ATE465168T1
ATE465168T1 AT00910581T AT00910581T ATE465168T1 AT E465168 T1 ATE465168 T1 AT E465168T1 AT 00910581 T AT00910581 T AT 00910581T AT 00910581 T AT00910581 T AT 00910581T AT E465168 T1 ATE465168 T1 AT E465168T1
Authority
AT
Austria
Prior art keywords
oligonucleotides
useful
xylo
lnas
configuration
Prior art date
Application number
AT00910581T
Other languages
English (en)
Inventor
Jesper Wengel
Original Assignee
Exiqon As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exiqon As filed Critical Exiqon As
Application granted granted Critical
Publication of ATE465168T1 publication Critical patent/ATE465168T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00910581T 1999-03-18 2000-03-17 Xylo-lna analoge ATE465168T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900382 1999-03-18
DKPA199901224 1999-09-01
PCT/DK2000/000125 WO2000056748A1 (en) 1999-03-18 2000-03-17 Xylo-lna analogues

Publications (1)

Publication Number Publication Date
ATE465168T1 true ATE465168T1 (de) 2010-05-15

Family

ID=26063889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910581T ATE465168T1 (de) 1999-03-18 2000-03-17 Xylo-lna analoge

Country Status (11)

Country Link
EP (1) EP1161439B1 (de)
JP (1) JP2002540118A (de)
KR (1) KR20020013513A (de)
CN (1) CN1350542A (de)
AT (1) ATE465168T1 (de)
AU (1) AU777049B2 (de)
CA (1) CA2368135C (de)
DE (1) DE60044241D1 (de)
HK (1) HK1048639A1 (de)
IL (1) IL145495A0 (de)
WO (1) WO2000056748A1 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60029314T2 (de) * 1999-03-24 2007-07-12 Exiqon A/S Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside
US6734291B2 (en) 1999-03-24 2004-05-11 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
AU2001247414A1 (en) 2000-03-14 2001-09-24 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US6936467B2 (en) 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
EP1268768A2 (de) 2000-03-27 2003-01-02 University Of Delaware Gezielte chromosomale genom-änderungen mit modifizierten einzelsträngigen oligonukleotiden
US20040009487A1 (en) * 2001-08-31 2004-01-15 Kadushin James M. Methods for blocking nonspecific hybridizations of nucleic acid sequences
EP1414840A4 (de) 2001-03-27 2005-04-13 Univ Delaware Genomics-anwendungen für modifizierte oligonukleotide
US6858726B2 (en) 2001-06-07 2005-02-22 Santaris Pharma A/S Synthesis of allofuranose
EP1397373B1 (de) * 2001-06-07 2005-02-16 Santaris Pharma A/S Verbesserte synthesen von allofuranose
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
CA2459347C (en) 2001-09-04 2012-10-09 Exiqon A/S Locked nucleic acid (lna) compositions and uses thereof
US7468244B2 (en) 2001-09-27 2008-12-23 University Of Delaware Polymorphism detection and separation
EP1446503A2 (de) 2001-09-27 2004-08-18 University Of Delaware Zusammensetzung und verfahren zur verbesserung der oligonukleotidgesteuerten veränderung von nukleinsäuresequenzen
WO2003039523A2 (en) * 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
WO2003075856A2 (en) 2002-03-07 2003-09-18 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
AU2003225495B2 (en) 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
US7005265B1 (en) 2002-06-20 2006-02-28 Wenhong Fan Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
ATE432347T1 (de) * 2002-06-24 2009-06-15 Exiqon As Methoden und systeme zur detektion und isolation von nucleinsäuresequenzen
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2004046160A2 (en) * 2002-11-18 2004-06-03 Santaris Pharma A/S Amino-lna, thio-lna and alpha-l-oxy-ln
AU2013201763B2 (en) * 2002-11-18 2015-05-07 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
DK1592793T3 (da) 2003-02-10 2009-10-26 Santaris Pharma As Oligomeriske forbindelser for modulation af Survivin ekspression
ATE432365T1 (de) * 2003-02-21 2009-06-15 Geneform Technologies Ltd Verfahren, kits und reagenzien zur nukleinsäuresequenzierung
ATE443765T1 (de) 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
CN1833034B (zh) 2003-06-20 2014-04-16 埃克斯魁恩公司 用于分析核酸混合物的探针、文库和试剂盒及其构建方法
WO2005061710A1 (en) * 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
US8192937B2 (en) 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
EP2290073A3 (de) 2004-05-28 2011-08-31 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
DE102004034343B4 (de) * 2004-07-10 2007-08-30 Olfert Landt Verfahren zum Nachweis von Spuren genomischer Varianten mittels Nukleinsäure-Amplifikationsreaktionen
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
WO2006050732A2 (en) 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
MX2007005558A (es) 2004-11-09 2008-01-31 Santaris Pharma As Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
EP2302055B1 (de) 2004-11-12 2014-08-27 Asuragen, Inc. Verfahren und Zusammensetzungen, die miRNAs und miRNAa-inhibitorischen Molekülen verbunden sind
EP1838870A2 (de) 2004-12-29 2007-10-03 Exiqon A/S Neue oligonukleotidzusammensetzungen und sondensequenzen mit eignung zum nachweis und zur analyse von micrornas und ihren ziel-mrnas
CN101238213B (zh) * 2005-05-25 2015-05-20 蒂纳控股有限责任公司 使用扭转嵌入核酸(TINA)稳定并选择性地形成Hoogsteen型三链体和双链体以及制备TINA的工艺
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
WO2007073149A1 (en) 2005-12-22 2007-06-28 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
WO2007107162A2 (en) 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
EP2007888A2 (de) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmazeutische zusammensetzung mit anti-mirna-antisense-oligonukleotiden
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
EP2090665A2 (de) 2006-10-20 2009-08-19 Exiqon A/S Neue humane MikroRNAs im Zusammenhang mit Krebs
EP3536788A1 (de) 2006-12-21 2019-09-11 QIAGEN GmbH Mikro-rna-zielortblockierende oligos und verwendungen davon
WO2008086807A2 (en) 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
US8470791B2 (en) 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
US8999634B2 (en) 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
CA2689602A1 (en) 2007-06-06 2008-12-18 Avi Biopharma, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
EP2623599B1 (de) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Mikromir-Moleküle
EP4053546A1 (de) 2007-12-06 2022-09-07 Genalyte, Inc. Vorrichtung und verfahren zur kennzeichnungsfreien überwachung von prozessen.
CA2708751A1 (en) 2007-12-14 2009-06-25 Minitube Of America, Inc. Gender-specific separation of sperm cells and embryos
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
EP3572796B8 (de) 2008-10-27 2023-01-18 Genalyte, Inc. Biosensoren basierend auf optischer sondierung und abtastung
US20110312094A1 (en) 2008-12-22 2011-12-22 Keygene N.V. Use of double stranded rna to increase the efficiency of targeted gene alteration in plant protoplasts
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2456870A1 (de) 2009-07-21 2012-05-30 Santaris Pharma A/S Auf pcsk9 gerichtete antisense-oligomere
WO2011032034A2 (en) 2009-09-10 2011-03-17 University Of Idaho Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
ES2465948T3 (es) 2010-04-30 2014-06-09 Exiqon A/S Procedimiento de hibridación in situ y tampón
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
US9243246B2 (en) 2010-08-24 2016-01-26 Sirna Therapeutics, Inc. Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
EP2635710B1 (de) 2010-11-05 2017-08-09 Genalyte, Inc. Optische analytnachweissysteme und anwendungsverfahren dafür
DK2646550T3 (en) 2010-12-02 2015-05-26 Keygene Nv Targeted DNA modification with oligonucleotides
EP2857512B1 (de) 2010-12-02 2016-06-29 Keygene N.V. Gezielte Änderung von DNA
BR112014001075A2 (pt) 2011-07-19 2016-11-29 Univ Idaho sonda, seu uso, método in vitro para associar uma sonda com um alvo e kit
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
SG10201913554YA (en) * 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3907506A1 (de) 2012-03-12 2021-11-10 The Board of Trustees of the University of Illinois Optische analytdetektionssysteme mit magnetischer verstärkung und verfahren zu deren verwendung
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
WO2014108759A1 (en) 2013-01-14 2014-07-17 Pierfrancesco Tassone INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
WO2014134144A1 (en) 2013-02-28 2014-09-04 The General Hospital Corporation Mirna profiling compositions and methods of use
WO2014143637A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
HUE048738T2 (hu) 2013-06-27 2020-08-28 Roche Innovation Ct Copenhagen As Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
WO2015075166A1 (en) 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
EP3099798B1 (de) 2014-01-29 2018-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Oligonukleotide und methoden zur inhibierung oder verminderung von bakteriellen biofilmen
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109474B (zh) 2014-08-19 2021-03-19 豪夫迈·罗氏有限公司 用于核酸检测的方法和组合物
US10533172B2 (en) 2014-09-18 2020-01-14 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
JP6835826B2 (ja) * 2015-08-24 2021-02-24 ロシュ イノベーション センター コペンハーゲン エーエス Ｌｎａ−ｇプロセス
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
EP3494219A1 (de) 2016-08-03 2019-06-12 Aalborg Universitet Zur hemmung von immun-checkpoint-proteinen designte antisense-oligonukleotide (aso)
EP3603648B1 (de) 2017-03-29 2025-09-17 Shionogi & Co., Ltd Komplex aus nukleinsäurearzneimittel und multiverzweigtem lipid
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
WO2019076919A1 (en) 2017-10-17 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) COMBINED TREATMENT OF CYSTIC FIBROSIS
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
CA3111562A1 (en) 2018-09-07 2020-04-02 The General Hospital Corporation Compositions and methods for immune checkpoint inhibition
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
EP3997225A1 (de) 2019-07-10 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von epilepsie
JP7692829B2 (ja) 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
US20230016983A1 (en) 2019-11-19 2023-01-19 lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Antisense oligonucleotides and thier use for the treatment of cancer
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
KR20230050336A (ko) 2020-07-10 2023-04-14 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) 뇌전증을 치료하기 위한 방법과 조성물
CN117280030A (zh) 2021-02-12 2023-12-22 梅兰德制药公司 用于治疗缺氧和缺血相关病症的药剂、组合物和方法
WO2022200633A1 (en) 2021-03-26 2022-09-29 Neumirna Therapeutics Aps Microrna-27b inhibitors
AU2022245292A1 (en) 2021-03-26 2023-10-12 Neumirna Therapeutics Aps Microrna-134 inhibitors
WO2022254021A1 (en) 2021-06-04 2022-12-08 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
CN118202050A (zh) 2021-08-17 2024-06-14 韩国科学技术院 靶向cav3.1基因的反义寡核苷酸及其用途
EP4388096A1 (de) 2021-08-19 2024-06-26 Neumirna Therapeutics ApS Antisense oligonukleotide gegen adenosinkinase
WO2023092102A1 (en) 2021-11-19 2023-05-25 Sanegene Bio Usa Inc. Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
WO2023152369A1 (en) 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
US20240002857A1 (en) 2022-05-09 2024-01-04 Sanegene Bio Usa Inc. Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
KR20250046303A (ko) 2022-08-05 2025-04-02 사네진 바이오 유에스에이 인크. 안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법
EP4332239A1 (de) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
KR20250088573A (ko) 2022-10-14 2025-06-17 사네진 바이오 유에스에이 인크. C3을 표적화하는 소형 간섭 rna 및 그의 용도
WO2024137590A2 (en) 2022-12-19 2024-06-27 Sanegene Bio Usa Inc. Small interfering rna targeting cfb and uses thereof
EP4646478A1 (de) 2023-01-06 2025-11-12 Institut National de la Santé et de la Recherche Médicale Intravenöse verabreichung von antisense-oligonukleotiden zur behandlung von schmerzen
US20240309383A1 (en) 2023-02-24 2024-09-19 Suzhou Sanegene Bio Inc. Small interfering rna targeting hbv and uses thereof
WO2024186673A2 (en) 2023-03-03 2024-09-12 Sanegene Bio Usa Inc. Small interfering rna targeting apoc3 and uses thereof
EP4450626A1 (de) 2023-04-21 2024-10-23 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Frnip2-inhibitoren zur behandlung von ataxie telangiectasia
CN121079412A (zh) 2023-04-28 2025-12-05 比姆医疗股份有限公司 经修饰的指导rna
WO2024263915A2 (en) 2023-06-21 2024-12-26 Sanegene Bio Usa Inc. Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
EP4512899A1 (de) 2023-08-23 2025-02-26 Lipigon Pharmaceuticals AB Angptl4-aso-zusammensetzungen zur behandlung von atherosklerose bei menschen
WO2025228441A2 (en) 2024-04-30 2025-11-06 Sanegene Bio Usa Inc. Small interfering rna targeting inhbe and uses thereof
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2026017140A2 (en) 2024-07-18 2026-01-22 Sanegene Bio Usa Inc. Small interfering rna targeting fxi and uses thereof
WO2026041067A2 (en) 2024-08-20 2026-02-26 Sanegene Bio Usa Inc. Small interfering rna targeting myostatin (mstn) and uses thereof
WO2026046411A1 (en) 2024-09-02 2026-03-05 Sanegene Bio Usa Inc. Small interfering rna targeting plasminogen (plg) and uses thereof
WO2026061986A1 (en) 2024-09-17 2026-03-26 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
WO2026068729A1 (en) 2024-09-26 2026-04-02 Neumirna Therapeutics Aps Antimir-27b for treatment of parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) * 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体

Also Published As

Publication number Publication date
EP1161439B1 (de) 2010-04-21
EP1161439A1 (de) 2001-12-12
WO2000056748A1 (en) 2000-09-28
IL145495A0 (en) 2002-06-30
CA2368135C (en) 2010-06-08
CA2368135A1 (en) 2000-09-28
CN1350542A (zh) 2002-05-22
JP2002540118A (ja) 2002-11-26
AU3274300A (en) 2000-10-09
KR20020013513A (ko) 2002-02-20
AU777049B2 (en) 2004-09-30
HK1048639A1 (zh) 2003-04-11
DE60044241D1 (de) 2010-06-02

Similar Documents

Publication Publication Date Title
ATE465168T1 (de) Xylo-lna analoge
DE69729292D1 (de) Kurze externe führungssequenzen
AU5121399A (en) Rna targeted 2'-modified oligonucleotides that are conformationally preorganized
CA2565103C (en) Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2000031235A3 (en) Nucleotide and protein sequences of nogo genes and methods based thereon
JPH06510791A (ja) 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
AU2002339458A1 (en) Sirna knockout assay method and constructs
EP1185546A4 (de) Hochspezifische primer, expressionsverfahren und "kit"
Froehler et al. Triple-helix formation and cooperative binding by oligodeoxynucleotides with a 3'-3'internucleotide junction
AU6589094A (en) 7-deazapurine modified oligonucleotides
CA2240494A1 (en) Therapeutic molecules generated by trans-splicing
WO2004029277A3 (en) Oligonucleotide conjugates
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
CA2434009A1 (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
SE9503117D0 (sv) Novel use of padlock probes
WO2001046394A3 (en) Mammalian protein phosphatases
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
Géci et al. Synthesis of twisted intercalating nucleic acids possessing acridine derivatives. Thermal stability studies
WO2003016528A3 (en) Oligonucleotide compositions and their use to induce apoptosis
WO2000027858A1 (en) Antisense oligonucleotides which inhibit telomerase's activity and their uses
WO2005039480A3 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
Ueno et al. Nucleosides and Nucleotides. 208. Alternate-Strand Triple-Helix Formation by the 3 ‘-3 ‘-Linked Oligodeoxynucleotides with the Anthraquinonyl Group at the Junction Point
ATE278011T1 (de) Human dnase ii
EP1210454A4 (de) Einflussnahme auf die shp-eprimierung durch antisense
HK1043155A1 (zh) 噬菌體t4基因35的基因及蛋白質排列

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties